Meningococcal disease in travelers: Update on vaccine options

Current Opinion in Infectious Diseases

Volumn 25, Issue 5, 2012, Pages 507-517

  Cramer, Jakob P ^a,b   Wilder Smith, Annelies ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

conjugate vaccines; meningitis; meningococcal disease; Neisseria meningitidis; traveler

Indexed keywords

BACTERIAL PROTEIN; BEXSERO; DIPHTHERIA VACCINE; GNA 1870; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; LP 2086; MCV4 CRM197; MCV4 DT; MCV4 TT; MCV4 VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

AFRICA; ANTIBODY PRODUCTION; ASIA; AUSTRALIA; EUROPE; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION RISK; MENINGITIS; MENINGOCOCCOSIS; MIDDLE EAST; NEISSERIA MENINGITIDIS; NEW ZEALAND; NONHUMAN; REVIEW; TRAVEL; VACCINATION; VIRUS STRAIN; WESTERN HEMISPHERE;

HUMANS; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; RISK FACTORS; TRAVEL; VACCINATION; WORLD HEALTH;

EID: 84865862567     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3283574c06     Document Type: Review

References (80)

1. Steffen R. The risk of meningococcal disease in travelers and current recommendations for prevention. J Travel Med 2010; 17 (Suppl):9-17.
2. Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J Travel Med 2010; 17 (Suppl):1-2.
3. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30 (Suppl 2):B26-B36.
4. Tzeng YL, Stephens DS. Epidemiology and pathogenesis of Neisseria meningitidis. Microbes Infect 2000; 2:687-700.
5. Rosenstein NE, Perkins BA, Stephens DS, et al. Meningococcal disease. N Engl J Med 2001; 344:1378-1388.
6. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:853-861.
7. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007; 369:2196-2210.
8. Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821-832.
9. Koch S, Steffen R. Meningococcal disease in travelers: vaccination recommendations. J Travel Med 1994; 1:4-7.
10. Boggild AK, Castelli F, Gautret P, et al. Vaccine preventable diseases in returned international travelers: results from the GeoSentinel Surveillance Network. Vaccine 2010; 28:7389-7395.
11. Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine 2011; 29:3363-3371.
12. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521-539.
13. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 (Suppl 2):B51-B63.
14. Wilder-Smith A. Meningococcal vaccines: a neglected topic in travel medicine? Expert Rev Vaccines 2009; 8:1343-1350.
15. Meningitis, meningococcal-France ex African meningitis belt. ProMED notification released on May 26th 2012. Available from: http://www. promedmail.org/direct.php?id=20120526.1145958. [Accessed 10 June 2012]
16. Leder K, Newman D. Respiratory infections during air travel. Intern Med J 2005; 35:50-55.
17. Wilder-Smith A, Tai Goh K. W-135 meningococcal disease in a traveler: a case report. J Travel Med 2003; 10:59-60.
18. O'Connor BA, Chant KG, Binotto E, et al. Meningococcal disease: probable transmission during an international flight. Commun Dis Intell 2005; 29:312-314.
19. Riley LK. Bacterial meningitis exposure during an international flight: lessons for communicable pathogens. Aviat Space Environ Med 2006; 77:758-760.
20. Rachael T, Schubert K, Hellenbrand W, et al. Risk of transmitting meningococcal infection by transient contact on aircraft and other transport. Epidemiol Infect 2009; 137:1057-1061.
21. Black S, Pizza M, Nissum M, Rappuoli R. Toward a meningitis-free world. Sci Transl Med 2012; 4:123s5.
22. Yaka P, Sultan B, Broutin H, et al. Relationships between climate and year-toyear variability in meningitis outbreaks: a case study in Burkina Faso and Niger. Int J Health Geogr 2008; 7:34.
23. Trotter CL, Greenwood BM. Meningococcal carriage in the African meningitis belt. Lancet Infect Dis 2007; 7:797-803.
24. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44:657-663.
25. Delrieu I, Yaro S, Tamekloe TA, et al. Emergence of epidemic Neisseria meningitidis serogroup × meningitis in Togo and Burkina Faso. PLoS One 2011; 6:e19513.
26. Wilder-Smith A, Chow A, Goh KT. Emergence and disappearance of W135 meningococcal disease. Epidemiol Infect 2010; 138:976-978.
27. Memish ZA. The Hajj: communicable and noncommunicable health hazards and current guidance for pilgrims. Euro Surveill 2010; 15:19671.
28. Novelli VM, Lewis RG, Dawood ST. Epidemic group A meningococcal disease in Haj pilgrims. Lancet 1987; 2:863.
29. Wilder-Smith A, Memish Z. Meningococcal disease and travel. Int J Antimicrob Agents 2003; 21:102-106.
30. Memish ZA, Venkatesh S, Ahmed QA. Travel epidemiology: the Saudi perspective. Int J Antimicrob Agents 2003; 21:96-101.
31. Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogrou W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis 2003; 9:665-671.
32. Wilder-Smith A, Barkham TM, Paton NI. Sustained outbreak of W135 meningococcal disease in east London, UK. Lancet 2002; 360:644-645.
33. Wilder-Smith A, Barkham TM, Earnest A, Paton NI. Acquisition of W135 meningococcal carriage in Hajj pilgrims and transmission to household contacts: prospective study. Br Med J 2002; 325:365-366.
34. Aguilera JF, Perrocheau A, Meffre C, Hahne S. Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000. Emerg Infect Dis 2002; 8:761-767.
35. Hahne SJ, Gray SJ, Jean F, et al. W135 meningococcal disease in England and Wales associated with Hajj 2000 and 2001. Lancet 2002; 359:582-583.
36. Balkhy HH, Memish ZA, Osoba AO. Meningococcal carriage among local inhabitants during the pilgrimage 2000-2001. Int J Antimicrob Agents 2003; 21:107-111.
37. Wilder-Smith A. W135 meningococcal carriage in association with the Hajj pilgrimage 2001: the Singapore experience. Int J Antimicrob Agents 2003; 21:112-115.
38. Balkhy HH, Memish ZA, Almuneef MA, Osoba AO. Neisseria meningitidis W-135 carriage during the Hajj season 2003. Scand J Infect Dis 2004; 36:264-268.
39. Dull PM, Abdelwahab J, Sacchi CT, et al. Neisseria meningitidis serogroup W-135 carriage among US travelers to the 2001 Hajj. J Infect Dis 2005; 191:33-39.
40. Dellicour S, Greenwood B. Systematic review: impact of meningococcal vaccination on pharyngeal carriage of meningococci. Trop Med Int Health 2007; 12:1409-1421.
41. Wilder-Smith A, Barkham TM, Chew SK, Paton NI. Absence of Neisseria meningitidis W-135 electrophoretic type 37 during the Hajj, 2002. Emerg Infect Dis 2003; 9:734-737.
42. Borrow R. Meningococcal disease and prevention at the Hajj. Travel Med Infect Dis 2009; 7:219-225.
43. Memish ZA, Goubeaud A, Broker M, et al. Invasive meningococcal disease and travel. J Infect Public Health 2010; 3:143-151.
44. Shao Z, Li W, Ren J, et al. Identification of a new Neisseria meningitidis serogroup C clone from Anhui province, China. Lancet 2006; 367:419-423.
45. Sexton K, Lennon D, Oster P, et al. Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand. N Z Med J 2004; 117:1.
46. Galloway Y, Stehr-Green P, McNicholas A, O'Hallahan J. Use of an observational cohort study to estimate the effectiveness of the New Zealand group B meningococcal vaccine in children aged under 5 years. Int J Epidemiol 2009; 38:413-418.
47. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines: an unfinished story. Lancet Infect Dis 2010; 10:112-124.
48. Ladhani SN, Lucidarme J, Newbold LS, et al. Invasive meningococcal capsular group Y disease, England and Wales, 2007-2009. Emerg Infect Dis 2012; 18:63-70.
49. Patel M, Lee CK. Polysaccharide vaccines for preventing serogroup A meningococcal meningitis. Cochrane Database Syst Rev 2005; CD001093.
50. Granoff DM, Gupta RK, Belshe RB, Anderson EL. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870-874.
51. Girard MP, Preziosi MP, Aguado MT, Kieny MP. A review of vaccine research and development: meningococcal disease. Vaccine 2006; 24:4692-4700.
52. Terranella A, Cohn A, Clark T. Meningococcal conjugate vaccines: optimizing global impact. Infect Drug Resist 2011; 4:161-169.
53. Pace D, Snape M, Westcar S, et al. A new combination Haemophilus influenzae type B and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine for primary immunization of infants. Pediatr Infect Dis J 2007; 26:1057-1059.
54. Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-367.
55. Trotter CL, Chandra M, Cano R, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36.
56. Menactra: FDA Memorandum January 14th 2005. Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProd ucts/UCM218548.pdf. [Accessed 9 June 2012]
57. Menactra: Package Insert. Available from: http://www.fda.gov/downloads/ BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM131170.pdf. [Accessed 9 June 2012]
58. Cho BH, Clark TA, Messonnier NE, et al. MCV vaccination in the presence of vaccine-associated Guillain-Barre syndrome risk: a decision analysis approach. Vaccine 2010; 28:817-822.
59. Macneil JR, Cohn AC, Zell ER, et al. Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J 2011; 30:451-455.
60. Borja-Tabora C, Montalban C, Memish Z, et al. Persistence of immune response up to 3 years following vaccination with MenACWY-TT meningococcal vaccine in subjects aged 11-55 years. Poster No 3, Northern European Conference of Travel Medicine (NECTM) 2012; Dublin, Ireland; 2012.
61. Poland GA. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Clin Infect Dis 2010; 50 (Suppl 2):S45-S53.
62. Findlow H, Borrow R, Andrews N, et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatr Infect Dis J 2012; 31:616-622.
63. Jodar L, LaForce FM, Ceccarini C, et al. Meningococcal conjugate vaccine for Africa: a model for development of new vaccines for the poorest countries. Lancet 2003; 361:1902-1904.
64. Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine 2012; 30 (Suppl 2):B40-B45.
65. Artenstein AW, Laforce FM. Critical episodes in the understanding and control of epidemic meningococcal meningitis. Vaccine 2012; 30:4701-4707.
66. Frasch C, Preziosi MP, Laforce FM. Development of a group A meningococcal conjugate vaccine, MenAfriVac (TM). Hum Vaccin Immunother 2012; 8.
67. Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983; 2:355-357.
68. Jennings HJ, Beurret M, Gamian A, Michon F. Structure and immunochemistry of meningococcal lipopolysaccharides. Antonie Van Leeuwenhoek 1987; 53:519-522.
69. Rappuoli R, Covacci A. Reverse vaccinology and genomics. Science 2003; 302:602.
70. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci USA 2006; 103:10834-10839.
71. Serruto D, Bottomley MJ, Ram S, et al. The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens. Vaccine 2012; 30 (Suppl 2):B87-B97.
72. Gossger N, Snape MD, Yu LM, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. J Am Med Assoc 2012; 307:573-582.
73. Beernink PT, Caugant DA, Welsch JA, et al. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and × strains from Africa. J Infect Dis 2009; 199:1360-1368.
74. Menveo: FDA Prescribing information. Available from: http://www.fda.gov/ downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm201349.pdf. [Accessed 9 June 2012]
75. Menveo: Summary of Product Characteristics (SmPC). Available from: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product-In formation/human/001095/WC500090147.pdf. [Accessed 9 June 2012]
76. Nimenrix: Summary of product characteristics (SmPC). Available from: http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/002226/WC500127663.pdf. [Accessed 9 June 2012]
77. El Bashir H, Heath PT, Papa T, et al. Antibody responses to meningococcal (groups A, C, Y and W135) polysaccharide diphtheria toxoid conjugate vaccine in children who previously received meningococcal C conjugate vaccine. Vaccine 2006; 24:2544-2549.
78. Harrison LH, Kreiner CJ, Shutt KA, et al. Risk factors for meningococcal disease in students in grades 9-12. Pediatr Infect Dis J 2008; 27:193-199.
79. Bilukha O, Messonnier N, Fischer M. Use of meningococcal vaccines in the United States. Pediatr Infect Dis J 2007; 26:371-376.
80. Ala'aldeen DA, Oldfield NJ, Bidmos FA, et al. Carriage of meningococci by university students, United Kingdom. Emerg Infect Dis 2011; 17:1762-1763.